Gilead’s Viread likely to be included in health insurance

The Health Insurance Review and Assessment Service (HIRA) said on Jun 28 that it would not list the U.S. drugmaker Gilead Sciences’ Viread (tenofovir) into the positive list unless Yuhan Corp., local exclusive distributor, accepts its insurance price that is lower than that of Bristol Myers Squibb (BMS)’s Baraclude (entecavir).

Last September in 2011, the Korea Food and Drug Administration g...